<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237718</url>
  </required_header>
  <id_info>
    <org_study_id>050377</org_study_id>
    <nct_id>NCT00237718</nct_id>
  </id_info>
  <brief_title>Provision of Antioxidant Therapy in Hemodialysis (PATH) Study</brief_title>
  <official_title>Provision of Antioxidant Therapy in Hemodialysis (PATH) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that end stage renal disease (ESRD) patients have higher levels of blood
      markers which their body makes in response to increased stress and injury. An increase in
      these markers have been shown to be related to cardiovascular disease and death in ESRD
      patients. This study will examine whether antioxidant therapy (Vitamin E and alpha lipoic
      acid) may decrease these markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxidative stress and acute phase inflammation are now recognized to be highly prevalent in
      the hemodialysis population, and several lines of evidence point to their contribution in
      atherosclerosis development. Biomarkers of the inflammatory state such as C-reactive protein
      (CRP) and interleukin-6 are robust predictors of cardiovascular events and mortality in the
      dialysis population. The uremic state is characterized by retention of oxidized solutes
      including reactive aldehyde groups and oxidized thiol groups. It has recently been
      demonstrated that initiation of maintenance hemodialysis does not improve biomarkers of
      oxidative stress or inflammation, suggesting that dialysis alone is inadequate to control the
      atherosclerotic uremic metabolic state. In this study we hypothesize that administration of
      antioxidant therapy will decrease biomarkers of acute phase inflammation and oxidative stress
      while improving the erythropoietic response in hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>F2-isoprostane (F2-iso)</measure>
    <time_frame>month 6</time_frame>
    <description>F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>month 6</time_frame>
    <description>IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>ALA and Vitamin E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha, gamma, beta, and delta (mixed) tocopherols</intervention_name>
    <description>approximately 666 IU daily (1 pill) for 6 months</description>
    <arm_group_label>ALA and Vitamin E</arm_group_label>
    <other_name>Vitamin E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha lipoic acid</intervention_name>
    <description>600 mg daily (2 pills 300 mg each) for 6 months</description>
    <arm_group_label>ALA and Vitamin E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for alpha lipoic acid; 2 pills daily for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with end-stage renal disease receiving thrice weekly hemodialysis

          2. Age &gt; 18 years

          3. Life expectancy greater than one year

          4. Ability to understand and provide informed consent for participation in the study

        Exclusion Criteria:

          1. AIDS (HIV seropositivity is not an exclusion criteria)

          2. Active malignancy excluding basal cell carcinoma of the skin

          3. Gastrointestinal dysfunction requiring parenteral nutrition

          4. History of functional kidney transplant &lt; 6 months prior to study entry

          5. Anticipated live donor kidney transplant over study duration

          6. History of poor adherence to hemodialysis or medical regimen

          7. Prisoners, patients with significant mental illness, pregnant women, and other
             vulnerable populations

          8. Patients taking vitamin E supplements &gt; 60 IU/day, vitamin C &gt; 500 mg/day over the
             past 30 days

          9. Patients taking anti-inflammatory medication except aspirin &lt; 325 mg/day over the past
             30 days

         10. Patients using a temporary catheter for dialysis access

         11. More than two hospitalizations within the last 90 days or one hospitalization within
             the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Himmelfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maine Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alp Ikizler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <results_first_submitted>September 1, 2011</results_first_submitted>
  <results_first_submitted_qc>September 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2011</results_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alp Ikizler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at the Vanderbilt University Medical Center and at Fresenius Medical Care North America Dialysis clinics between April 2006 and September 2010.</recruitment_details>
      <pre_assignment_details>There is a 1-month period between enrollment and assignment to a treatment group. Although 385 subjects were enrolled, only 356 were randomized (29 subjects withdrew consent prior to randomization). Also, 31 subjects were administratively withdrawn (due to widespread protocol non-compliance at one site) leaving 325 subjects assigned to a group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALA and Vitamin E</title>
          <description>600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALA and Vitamin E</title>
          <description>600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="325"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12"/>
                    <measurement group_id="B2" value="58" spread="13"/>
                    <measurement group_id="B3" value="58" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>F2-isoprostane (F2-iso)</title>
        <description>F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress.</description>
        <time_frame>month 6</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 6-month study. Note that 8 subjects were excluded due to samples being lost. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ALA and Vitamin E</title>
            <description>600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>F2-isoprostane (F2-iso)</title>
          <description>F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 6-month study. Note that 8 subjects were excluded due to samples being lost. The analysis was per protocol.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.077" spread="0.062"/>
                    <measurement group_id="O2" value="0.073" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6 (IL-6)</title>
        <description>IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response.</description>
        <time_frame>month 6</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 6-month study. Note that 8 subjects were excluded due to samples being lost. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ALA and Vitamin E</title>
            <description>600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 (IL-6)</title>
          <description>IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 6-month study. Note that 8 subjects were excluded due to samples being lost. The analysis was per protocol.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="15"/>
                    <measurement group_id="O2" value="20" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ALA and Vitamin E</title>
          <description>600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>electrolyte disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>lesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>access related</sub_title>
                <description>Any adverse event related to the dialysis access (catheter, graft, or fistula).</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>hypertension/hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="63" subjects_affected="44" subjects_at_risk="160"/>
                <counts group_id="E2" events="44" subjects_affected="33" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="160"/>
                <counts group_id="E2" events="48" subjects_affected="36" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="160"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>access related</sub_title>
                <description>Any adverse event related to the dialysis access (catheter, graft, or fistula).</description>
                <counts group_id="E1" events="44" subjects_affected="22" subjects_at_risk="160"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>T. Alp Ikizler, MD</name_or_title>
      <organization>Vanderbilt University</organization>
      <email>alp.ikizler@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

